|
|
| Product Name: | GTCpFE | | Synonyms: | GTCpFE;2-Butenedioic acid (2E)-, 1-[[4-[[2-(acetyloxy)benzoyl]oxy]phenyl]methyl] 4-ethyl ester | | CAS: | 1588866-45-8 | | MF: | C22H20O8 | | MW: | 412.39 | | EINECS: | | | Product Categories: | | | Mol File: | 1588866-45-8.mol |  |
| | GTCpFE Chemical Properties |
| Boiling point | 551.452±45.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.263±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) |
| | GTCpFE Usage And Synthesis |
| Uses | GTCpFE inhibits IKKα/β in the NF-κB pathway with anti-inflammatory activities and blocks p65 nuclear entry, which consists of Dimethyl fumarate (DMF) (HY-17363) linked to Aspirin (ASA) (HY-14654). GTCpFE exhibits selective anti-cancer stem-like cell (CSC) activity by reducing mammosphere growth and the CD44+ CD24- immunophenotype. GTCpFE inhibits breast cancer stem cells, an important NFκB- and PGE2-dependent phenotype in aggressive cancers[1][2]. | | References | [1] Kastrati I, et al. Design and synthesis of hybrid drugs to target inflammatory pathways in breast cancer[J]. Cancer Research, 2015, 75(15_Supplement): 4497-4497.
[2] Kastrati I, et al. A novel aspirin prodrug inhibits NFκB activity and breast cancer stem cell properties. BMC Cancer. 2015 Nov 4;15:845. DOI:10.1186/s12885-015-1868-7 |
| | GTCpFE Preparation Products And Raw materials |
|